- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00054392
Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
A Randomized, Phase III Multicenter Trial Of Gemcitabine In Combination With Carboplatin Or Paclitaxel Plus Carboplatin In Patients With Metastatic (Stage IIIB, IV) Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy such as gemcitabine, carboplatin, and paclitaxel use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective in treating non-small cell lung cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of different combination chemotherapy regimens in treating patients who have stage IIIB, stage IV, or recurrent non-small cell lung cancer.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
OBJECTIVES:
- Compare the overall survival of patients with stage IIIB or IV or recurrent non-small cell lung cancer treated with gemcitabine and carboplatin vs gemcitabine and paclitaxel vs paclitaxel and carboplatin.
- Compare the overall response rate and time to progression in patients treated with these regimens.
- Compare the toxic effects of these regimens in these patients.
- Compare the quality of life of patients treated with these regimens.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to weight loss within the past 6 months (less than 5% vs at least 5%), disease stage (IIIB vs IV), and brain metastases (present vs absent). Patients are randomized to 1 of 3 treatment arms.
- Arm I: Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and carboplatin IV over 15-30 minutes on day 1.
- Arm II: Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and paclitaxel IV over 3 hours on day 1.
- Arm III: Patients receive paclitaxel IV over 3 hours and carboplatin IV over 15-30 minutes on day 1.
In all arms, treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline, every 6 weeks during study treatment, and then every 3 months until progressive disease is documented.
Patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 1,134 patients (378 per treatment arm) will be accrued for this study within 2 years.
Tipo de estudio
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
California
-
Loma Linda, California, Estados Unidos, 92354
- Loma Linda University Cancer Institute at Loma Linda University Medical Center
-
Pomona, California, Estados Unidos, 91767
- New Hope Cancer and Research Institute - Pomona
-
-
Connecticut
-
New London, Connecticut, Estados Unidos, 06320
- Lawrence and Memorial Hospital
-
-
Florida
-
Gainesville, Florida, Estados Unidos, 32610-0383
- University of Florida Shands Cancer Center
-
Lakeland, Florida, Estados Unidos, 33805
- Lakeland Regional Cancer Center at Lakeland Regional Medical Center
-
Panama City, Florida, Estados Unidos, 32405-4587
- Gulf Coast Cancer Treatment Center
-
-
Georgia
-
Decatur, Georgia, Estados Unidos, 30033
- Veterans Affairs Medical Center - Atlanta (Decatur)
-
-
Illinois
-
Harvey, Illinois, Estados Unidos, 60426
- Ingalls Cancer Care Center at Ingalls Memorial Hospital
-
Urbana, Illinois, Estados Unidos, 61801
- Carle Cancer Center at Carle Foundation Hospital
-
-
Indiana
-
New Albany, Indiana, Estados Unidos, 47150
- Cancer Center of Indiana
-
South Bend, Indiana, Estados Unidos, 46601
- CCOP - Northern Indiana CR Consortium
-
-
Maryland
-
Annapolis, Maryland, Estados Unidos, 21401
- Annapolis Oncology Center
-
Baltimore, Maryland, Estados Unidos, 21201
- Greenebaum Cancer Center at University of Maryland Medical Center
-
Baltimore, Maryland, Estados Unidos, 21204
- Greater Baltimore Medical Center Cancer Center
-
-
Massachusetts
-
Springfield, Massachusetts, Estados Unidos, 01107
- Baystate Regional Cancer Program at D'Amour Center for Cancer Care
-
Worcester, Massachusetts, Estados Unidos, 01608
- Fallon Clinic at Worcester Medical Center
-
-
Michigan
-
Kalamazoo, Michigan, Estados Unidos, 49007-3731
- West Michigan Cancer Center
-
-
Montana
-
Great Falls, Montana, Estados Unidos, 59405
- Sletten Regional Cancer Institute at Benefis Healthcare
-
-
New Jersey
-
Flemington, New Jersey, Estados Unidos, 08822
- Hunterdon Regional Cancer Center at Hunterdon Medical Center
-
Howell, New Jersey, Estados Unidos, 07731
-
Neptune, New Jersey, Estados Unidos, 07754
- Jersey Shore Cancer Center at Jersey Shore University Medical Center
-
Pomona, New Jersey, Estados Unidos, 08240
- Atlanticare Regional Medical Center
-
Trenton, New Jersey, Estados Unidos, 08618
- Mercer Bucks Oncology-Hematology
-
-
New York
-
Buffalo, New York, Estados Unidos, 14263-0001
- Roswell Park Cancer Institute
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27599-7295
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
-
Fayetteville, North Carolina, Estados Unidos, 28302-2000
- Cape Fear Valley Medical Center
-
Greenville, North Carolina, Estados Unidos, 27834
- Leo W. Jenkins Cancer Center at ECU Medical School
-
-
Ohio
-
Canton, Ohio, Estados Unidos, 44710-1799
- Aultman Hospital Cancer Center at Aultman Health Foundation
-
Cleveland, Ohio, Estados Unidos, 44195
- Cleveland Clinic Taussig Cancer Center
-
Cleveland, Ohio, Estados Unidos, 44111
- Cleveland Clinic Cancer Center at Fairview Hospital
-
Parma, Ohio, Estados Unidos, 44129
- Parma Community General Hospital
-
-
Pennsylvania
-
Abington, Pennsylvania, Estados Unidos, 19001
- Rosenfeld Cancer Center at Abington Memorial Hospital
-
Chambersburg, Pennsylvania, Estados Unidos, 17201
- Falling Spring Medical Associates
-
Dunmore, Pennsylvania, Estados Unidos, 18512
- Hematology-Oncology Associates of Northeastern Pennsylvania
-
Harrisburg, Pennsylvania, Estados Unidos, 17110
- PinnacleHealth Regional Cancer Center at Polyclinic Hospital
-
Kittanning, Pennsylvania, Estados Unidos, 16201
- Richard G. Laube Cancer Center at ACMH
-
Lancaster, Pennsylvania, Estados Unidos, 17605-0396
- Lancaster Cancer Center
-
Lemoyne, Pennsylvania, Estados Unidos, 17043
- Central Pennsylvania Hematology and Medical Oncology Associates, PC
-
Paoli, Pennsylvania, Estados Unidos, 19301
- Paoli Hematology-Oncology PC at Paoli Memorial Hospital
-
Philadelphia, Pennsylvania, Estados Unidos, 19102
- Drexel University College of Medicine - Center City Hahnemann Campus
-
Philadelphia, Pennsylvania, Estados Unidos, 19102-1192
- Hahnemann University Hospital
-
Philadelphia, Pennsylvania, Estados Unidos, 19107-5541
- Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
-
Philadelphia, Pennsylvania, Estados Unidos, 19106
- Pennsylvania Oncology Hematology Associates, Incorporated - Philadelphia
-
Philadelphia, Pennsylvania, Estados Unidos, 19104-4283
- Fox Chase Cancer Center CCOP Research Base
-
Pittsburgh, Pennsylvania, Estados Unidos, 15232
- Hillman Cancer Center at University of Pittsburgh Cancer Institute
-
Pittsburgh, Pennsylvania, Estados Unidos, 15212-4772
- Allegheny Cancer Center at Allegheny General Hospital
-
Pottstown, Pennsylvania, Estados Unidos, 19464
- Pottstown Memorial Regional Cancer Center
-
Reading, Pennsylvania, Estados Unidos, 19603
- St. Joseph Medical Center
-
Wynnewood, Pennsylvania, Estados Unidos, 19096
- Lankenau Cancer Center at Lankenau Hospital
-
-
South Carolina
-
Columbia, South Carolina, Estados Unidos, 29210
- South Carolina Oncology Associates, PA
-
Myrtle Beach, South Carolina, Estados Unidos, 29572
- Coastal Cancer Center - Myrtle Beach
-
-
Tennessee
-
Collierville, Tennessee, Estados Unidos, 38077
- Family Cancer Center, PLLC - Collierville
-
Knoxville, Tennessee, Estados Unidos, 37901
- Baptist Regional Cancer Center at Baptist Hospital of East Tennessee
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22908
- University of Virginia Cancer Center at UV Health System
-
-
West Virginia
-
Charleston, West Virginia, Estados Unidos, 25304-1297
- David Lee Outpatient Cancer Center at Charleston Area Medical Center
-
Morgantown, West Virginia, Estados Unidos, 26505
- Morgantown Internal Medicine Group, Incorporated
-
Morgantown, West Virginia, Estados Unidos, 26506-9162
- Mary Babb Randolph Cancer Center at West Virginia University Hospitals
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
DISEASE CHARACTERISTICS:
Histologically confirmed non-small cell lung cancer (NSCLC) of 1 of the following types:
- Squamous cell
- Adenocarcinoma
- Large cell anaplastic
- Bronchoalveolar
- Non-small cell carcinoma not otherwise specified NOTE: Mixed tumors are categorized by the predominant cell type (tumors with small-cell anaplastic elements are ineligible)
Evidence of at least 1 of the following:
- Clinically documented recurrent disease after prior radiation or surgery
- Stage IV disease (distant metastases)
Stage IIIB disease presenting with 1 of the following:
- Pleural or pericardial effusion by CT scan or chest x-ray
- Pleural implants documented pathologically or seen on CT scan or x-ray
- Measurable or evaluable disease
- No brain metastases unless clinically stable after surgery and/or radiotherapy
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- ECOG 0-1
Life expectancy
- Not specified
Hematopoietic
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
Hepatic
- Bilirubin no greater than 1.5 mg/dL
- AST less than 5 times upper limit of normal
Renal
- Creatinine no greater than 1.5 mg/dL OR
- Creatinine clearance at least 40 mL/min
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No hypersensitivity to agents that contain Cremophor EL (polyoxyethylated castor oil)
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- No prior chemotherapy for advanced NSCLC
Endocrine therapy
- Not specified
Radiotherapy
- See Disease Characteristics
- Recovered from prior radiotherapy
- No prior radiotherapy to the only site of measurable disease, unless the site had subsequent progression of disease documented by physical exam, radiography, or pathology
- No concurrent radiotherapy (except for brain metastases)
Surgery
- See Disease Characteristics
Other
- No concurrent aminoglycoside antibiotics
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
---|
Supervivencia
|
Medidas de resultado secundarias
Medida de resultado |
---|
Tiempo hasta la progresión de la enfermedad
|
Tasa de respuesta tumoral
|
Quality of life as measured by the Functional Assessment of Cancer -Lung (FACT-L) questionnaire at baseline, every 6 weeks during study treatment, and then every 3 months thereafter
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Silla de estudio: Joseph A. Treat, MD, Fox Chase Cancer Center
Publicaciones y enlaces útiles
Publicaciones Generales
- Edelman MJ, Belani CP, Socinski MA, Ansari RH, Obasaju CK, Chen R, Monberg MJ, Treat J; Alpha Oncology Research Network. Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. J Thorac Oncol. 2010 Jan;5(1):110-6. doi: 10.1097/JTO.0b013e3181c59a3a.
- Obasaju CK, Ansari RH, Socinski MA, Chen R, Monberg MJ, Catalano RB, Marinucci DM, Liles DK, Ribeiro MJ, Comis RL, Treat J; Alpha Oncology Research Network. A Comparison of white and African American outcomes from a three-arm, randomized, phase III multicenter trial of advanced or metastatic non-small cell lung cancer. J Thorac Oncol. 2010 Jul;5(7):993-1000. doi: 10.1097/jto.0b013e3181e29cf3.
- Treat JA, Gonin R, Socinski MA, Edelman MJ, Catalano RB, Marinucci DM, Ansari R, Gillenwater HH, Rowland KM, Comis RL, Obasaju CK, Belani CP; Alpha Oncology Research Network. A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer. Ann Oncol. 2010 Mar;21(3):540-547. doi: 10.1093/annonc/mdp352. Epub 2009 Oct 15.
- Treat J, Edelman MJ, Belani CP, Socinski MA, Monberg MJ, Chen R, Obasaju CK; Alpha Oncology Research Network. A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. Lung Cancer. 2010 Dec;70(3):340-6. doi: 10.1016/j.lungcan.2010.02.011. Epub 2010 Mar 27.
- Treat J, Belani CP, Edelman MJ, et al.: A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (Stage IIIB, IV) non-small cell lung cancer (NSCLC): update of the Alpha Oncology trial (A1-99002L). [Abstract] J Clin Oncol 23 (Suppl 16): A-LBA7025, 627s, 2005.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
- cáncer de pulmón de células no pequeñas recurrente
- cáncer de pulmón de células no pequeñas en estadio IIIB
- cáncer de pulmón de células no pequeñas en estadio IV
- cáncer de pulmón de células escamosas
- cáncer de pulmón de células grandes
- adenocarcinoma de pulmón
- cáncer de pulmón de células adenoescamosas
- cáncer de pulmón de células broncoalveolares
Términos MeSH relevantes adicionales
- Enfermedades de las vías respiratorias
- Neoplasias
- Enfermedades pulmonares
- Neoplasias por sitio
- Neoplasias de las vías respiratorias
- Neoplasias torácicas
- Carcinoma Broncogénico
- Neoplasias Bronquiales
- Neoplasias Pulmonares
- Carcinoma de pulmón de células no pequeñas
- Efectos fisiológicos de las drogas
- Mecanismos moleculares de acción farmacológica
- Agentes antiinfecciosos
- Agentes Antivirales
- Inhibidores de enzimas
- Antimetabolitos, Antineoplásicos
- Antimetabolitos
- Agentes antineoplásicos
- Agentes inmunosupresores
- Factores inmunológicos
- Moduladores de tubulina
- Agentes antimitóticos
- Moduladores de mitosis
- Agentes antineoplásicos, fitogénicos
- Gemcitabina
- Carboplatino
- Paclitaxel
Otros números de identificación del estudio
- ALPHA-A1-99002L
- CDR0000270434 (Identificador de registro: PDQ (Physician Data Query))
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer de pulmón
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
-
Dana-Farber Cancer InstituteTerminadoCancer de RIÑON | Cancer de prostata | Cáncer genitourinarioEstados Unidos
-
Rabin Medical CenterReclutamiento
Ensayos clínicos sobre carboplatino
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)RetiradoCáncer de pulmón de células no pequeñas en estadio IIIA | Cáncer de pulmón de células no pequeñas en estadio IIIB | Cáncer de pulmón de células escamosas | Adenocarcinoma de pulmón | Cáncer de pulmón de células grandes | Cáncer de pulmón de células no pequeñas en estadio IIA | Cáncer de pulmón...
-
Children's Oncology GroupNational Cancer Institute (NCI)TerminadoTumor cerebral | Tumor del sistema nervioso centralEstados Unidos, Canadá, Australia, Suiza, Países Bajos, Nueva Zelanda